Advancing Real-Time Clinical Trials

Why It Matters

Real‑time trials could shave months off drug approvals, delivering life‑saving therapies faster while maintaining safety, reshaping the biotech landscape.

Key Takeaways

• FDA launches first real‑time clinical trial, viewing data live in the cloud
• Dead time now 45% of drug development, driving push for automation
• AI and cloud tools cut filing review from months to minutes
• Bayesian stats allow early trial stops for efficacy or safety
• Partnerships with M.D. Anderson, Penn, and Paradigm Health enable rollout

Summary

The FDA announced a landmark initiative: the first ever real‑time clinical trial, where regulators can monitor safety signals and efficacy endpoints instantly via a cloud‑based dashboard. Commissioner Dr. Marty Makary framed the effort as a response to the growing "dead time"—now 45% of the drug development timeline—spent on paperwork, data entry, and manual analysis, which delays patient access to new therapies.

Key data points highlighted include the staggering 66‑million‑page application example and the shift from a 10‑12‑year drug approval horizon to a potential acceleration of months. By leveraging AI, cloud computing, and electronic health records, the FDA aims to reduce filing periods from two months to minutes, employ Bayesian statistics for early trial termination, and streamline IRB and pre‑IND processes.

Speakers from M.D. Anderson, the University of Pennsylvania, AstraZeneca, Amgen, and Paradigm Health underscored the collaborative nature of the project. They demonstrated a live dashboard showing real‑time tumor measurements and adverse events, and emphasized that the technology enables faster decision‑making without compromising safety.

The broader implication is a reengineered drug development pipeline that could restore U.S. leadership in biotech, improve pandemic preparedness, and deliver cures faster to patients. If successful, the model may become the new standard, reducing costs, expanding trial access, and shortening the gap between discovery and market approval.

Original Description

The U.S. Food and Drug Administration will announce two major steps as part of an initiative to advance the implementation of real-time clinical trials (RTCT).

WHO:

• Commissioner of Food and Drugs Marty Makary, MD, MPH 

• FDA Chief AI Officer Jeremy Walsh  

• FDA Deputy Chief Medical Officer Mallika Mundkur, MD 

• Industry leaders from Amgen, AstraZeneca, Paradigm Health, the University of Pennsylvania Health System and University of Texas MD Anderson Cancer Center.